維力醫療(603309.SH):擬設立印尼孫公司並投資建設印尼生產基地
格隆匯5月21日丨維力醫療(603309.SH)公佈,公司擬通過全資子公司WELL
LEAD GLOBAL
LIMITED(維力環球有限公司)作為出資主體,與公司董事長、實際控制人向彬先生共同投資設立印尼孫公司,並投資建設印尼生產基地,項目總投資500億印尼盾(摺合人民幣約2,000萬人民幣,實際投資金額以相關主管部門批准金額為準),其中維力環球有限公司出資475億印尼盾,持股95%,向彬出資25億印尼盾,持股5%。
本次公司通過全資子公司與關聯方共同出資在印尼設立孫公司投資建設生產基地,是基於公司的業務發展需要和完善海外戰略佈局的重要舉措。公司產能目前集中在國內,本次在印尼投資新建生產基地,可以更好地開拓國際市場及應對海外客户的需求,進一步完善公司全球化製造的佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.